Novartis Skips Weight Loss Drug 'Frenzy,' Focuses on 'Unique Position' for Cancer, Alzheimers, and Parkinsons Treatments

Novartis CEO Vas Narasimhan stated that the company will not compete in the "frenzy" of the weight loss drug market dominated by Novo Nordisk and Eli Lilly. Novartis will instead focus on areas where it can build a “unique position,” including treatments for diseases like Alzheimer’s, Parkinson’s, and various cancers. The company is particularly optimistic about its therapies for cancer, which could become a $20 billion business.